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Serological Evidence of Human Granulocytic Ehrlichiosis 
in Switzerland 
N. Pusterla, R. Weber, C. Wolfensberger, G. Schfir, R. Zbinden, W. Fierz, 
J. E. Madigan, J. S. Dumler, H. Lutz 
Abstract To investigate whether human granulocytic 
ehrlichiosis (HGE)  is prevalent in Switzerland, 1515 
human serum samples from individuals with different 
risks for tick exposure were tested for antibodies to 
Ehrlichia phagocytophila,  surrogate marker of the 
agent of HGE.  The distribution of titres showed 
marked differences between sera of individuals with no 
or low risk for tick exposure and those with a high risk. 
The results of serological testing provided evidence of 
HGE in Switzerland as well as evidence of two types of 
coinfections: those with the agent of HGE and BorreIia 
burgdorferi, and those with the agent of HGE and the 
central European tickborne encephalitis virus. 
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Introduction 
Human granulocytic ehrlichiosis (HGE)  is an acute, fe- 
brile disease with nonspecific symptoms, often accom- 
panied by leukopenia, thrombocytopenia, anaemia, and 
a mild elevation of the transaminases [1]. Ticks of the 
genus Ixodes, which transmit BorreIia burgdorferi and 
the central European tickborne encephalitis virus, are 
also the likely vector of the agent of HGE.  Information 
concerning the agent responsible for HGE and its dis- 
tribution outside the USA is sparse. Epidemiological 
studies in Sweden [2], Norway [3], the UK [4], and 
northern Switzerland [5] indicate that HGE is endemic 
in those countries. Recently, investigators in Slovenia 
provided serological and molecular evidence of HGE 
in their country [6]. Because of the marked serological 
cross-reactivity between the members of the Ehrlichia 
phagocytophila genogroup, Ehrlichia equi and Ehrli- 
chia phagocytophila, ntigen can be used in serological 
tests for HGE [7]. 
In the present study, sera from 1515 individuals from 
five risk groups were investigated to determine the pre- 
valence, if any, of HGE in Switzerland. 
Materials and Methods 
Sera from 1515 persons from five groups representing different 
risk categories for tick exposure were collected between January 
1993 and December 1996 and tested for antibodies to Ehrlichia 
phagocytophila by indirect immunofluorescence. All persons re- 
sided in the eastern region of Switzerland. 
Group 1 consisted of 373 newborn babies from which umbilical 
cord blood was collected, and group 2 was composed of 530 ran- 
dom blood donors. Group 3 consisted of 258 recreational hunters 
who were assumed to have a high risk of tick exposure due to 
their weekly hunting activities. Group 4 consisted of 149 patients 
who had been diagnosed previously with Lyme borreliosis by 
their own physicians on the basis of clinical evaluation and anti- 
body to Borrelia burgdorferi screened by enzyme immunoassay 
(EIA) and confirmed by immunoblotting. The 205 patients in 
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group 5 had been diagnosed previously with acute central Euro- 
pean fickborne ncephalitis on the basis of clinical evaluation and 
a positive EIA test for antibodies to the central European tick- 
borne encephalitis virus. 
All serum samples were examined for antibodies to Ehrlichia 
phagocytophila (Swiss strain) by indirect immunofluorescence as 
described previously [8]. Values _>80 were considered positive, 
because nonspecific reactivity is likely to occur in less diluted se- 
rum. Values from the five groups were compared using the chi- 
square test. P values _<0.05 were considered statistically signifi- 
cant. 
Table 1 lists the reference sera and conjugated antisera used to 
determine possible cross-reactivity with Ehrlichia phagocytophila 
antigen via indirect immunofluorescence. S ra from four human 
patients with HGE acquired in the USA (provided by J.S. Dump 
er, the Johns Hopkins University School of Medicine, Baltimore, 
USA), and sera from three horses experimentally infected with 
HGE (provided by J.E. Madigan, University of California, Davis, 
USA) were drawn during the acute phase of infection and again 
approximately 30 days later. 
Results and Discussion 
Our approach was to examine groups of individuals 
with different risk factors for tick exposure. Group 1 
comprised newborns, chosen because tick exposure can 
be safely ruled out in these subjects; 99.5% of the sera 
from this group had a negative antibody titre (Table 2). 
Two samples had titres of 80, which may have reflected 
maternal antibodies. Unfortunately,  maternal serum 
samples were not available to confirm our suspicion. In 
comparison, 0.85% of babies born to mothers living in 
Switzerland had positive titres for Borre l ia  burgdor fe r i  
[9]. Group 2, consisting of randomly chosen blood do- 
nors, was presumed to represent individuals with a rela- 
tively low, or average, risk of tick exposure; however, 
because the donors remained anonymous,  the true ex- 
posure rate was unknown. Of the samples from this 
group, 98.9% had a titre of <80, and only six (1.1%) 
had a titre of 80. Group 3 comprised hunters, who were 
chosen because they, by virtue of their recreational ac- 
tivity, can be expected to have a higher risk of tick bites 
compared with the average population. This expecta- 
tion was borne out by a statistically significant higher 
incidence of positive titres (9%) in this group as com- 
pared with groups 1 and 2 (p < 0.001). 
As expected, the highest seroprevalence occurred in in- 
dividuals seropositive for Borre l ia  burgdor fe r i  (12.7%) 
or the central European t ickborne encephalitis virus 
(19.5%). Compared with groups 1 and 2, these differ- 
Table 1 Reference sera and 
conjugated antisera used to 
determine specificity 
Reference serum Species Conjugated antiserum 
Coxiella burnetti a bovine FITC conjugated 
Ehrlichia canis a canine FITC conjugated 
Ehrlichia risticii a equine FITC conjugated 
Ehrlichia chaffeensis b human FITC conjugated 
Rickettsia rickettsii b human FITC conjugated 
Rickettsia typhi b human FITC conjugated 
Brucella abortus a bovine FITC conjugated 
Anaplasma marginale a bovine FITC conjugated 
Babesia bovis a bovine FITC conjugated 
Babesia divergens a bovine FITC conjugated 
rabbit anti-bovine IgG ~ 
rabbit anti-dog IgG d 
goat anti-horse IgG e 
goat anti-human IgG f 
goat anti-human IgG f 
goat anti-human IgG f 
rabbit anti-bovine IgG ~ 
rabbit anti-bovine IgG ~ 
rabbit anti-bovine IgG ~ 
rabbit anti-bovine IgG r 
a Reference sera were obtained from the U.S. National Veterinary Services Laboratories (Ames, 
Iowa) 
b Reference sera obtained from J. S. Dumler, the Johns Hopkins University School of Medicine 
(Baltimore, Maryland) 
c Rabbit anti-bovine/FITC, Nordic Immunological Laboratories b.v., The Netherlands 
aFluorescein_conjugated affinipure rabbit anti-dog IgG, Jackson ImmunoResearch Laboratories, 
Inc., USA 
e Goat anti-horse IgG affin. FITC-conjugated, Chemical Credential, USA 
f Fluorescein-conjugated affinipure goat anti-human IgG, Jackson ImmunoResearch Laboratories, 
Inc., USA 
Table 2 Distribution of titres 
to Ehrlichia phagocytophila in 
five groups of individuals with 
different risk categories for 
tick exposure 
Group No. (%) 
(no. of samples) 
Titer < 80 Titer = 80 Titer = 160 
Newborns (373) 371 (99.5) 2 (0.5) 0 
Blood donors (530) 524 (98.9) 6 (1.1) 0 
Hunters (258) 235 (91.0) 19 (7.4) 4 (1.6) 
Patients with Lyme 130 (87.3) 13 (8.7) 6 (4.0) 
borreliosis (149) 
Patients with CETE (205) 165 (80.5) 35 (17.1) 5 (2.4) 
Total (1515) 1425 (94.0) 75 (5.0) 15 (1.0) 
CETE, central European tickborne ncephalitis 
ences were statistically significant (p < 0.001). Other in- 
vestigators from Norway [3] and Switzerland [5] have 
studied patients with Lyme disease for antibodies to the 
Ehrlichia equi antigen, and found a comparable sero- 
prevalence of 10.2% and 17.1%, respectively. Unlike 
Borrelia burgdorferi, the virus causing central Euro- 
pean tickborne encephalitis has a markedly heteroge- 
neous geographic distribution in Switzerland and oc- 
curs predominantly in so-called natural loci [10]. This 
distribution may explain the low discrepancy between 
the number of positive serum samples in groups 4 and 
5. 
Reference sera used for determination of cross-reactivi- 
ty had antibody titres to Ehrlichia phagocytophila of 10 
or 20; the exception was Ehrlichia chaffeensis seroposi- 
tive reference sera, which had a titre to Ehrlichia pha- 
gocytophila of 40. All acute and postinfection sera with 
documented acute HGE infection showed seroconver- 
sion: a two- to four-fold increase in titres was observed 
in sera from humans, and a four- to seven-fold increase 
in titres was found in sera from equines. 
Of the four human patients with HGE from whom 
paired sera were collected, two had titres of 40 thirty 
days after the acute phase. According to the criteria de- 
scribed, these results would have been classified as 
negative. The minimal increase in titre in these two pa- 
tients might be explained by the relatively rapid recov- 
ery of these individuals following antibiotic treatment 
and the fact that a decreased bacterial oad may have 
favoured a low seroresponse. Another possible expla- 
nation is that antigenic structural diversity could exist 
among otherwise indistinguishable granulocytic ehrli- 
chial isolates. Nevertheless, we assumed that the specif- 
icity and sensitivity of our anti-Ehrlichia phagocytophi- 
la antibody test was acceptable, and thus, the Ehrlichia 
phagocytophila antigen was suitable for detection of se- 
rum antibodies to the agent of HGE acquired in Eu- 
rope. 
We realise that findings from serological examinations 
to detect an infection that has not yet been identified in 
Switzerland by clinical observations, by direct detection 
of the organism, or by molecular techniques, must be 
interpreted with caution. However, several observa- 
tions indicate that the occurrence of HGE in Switzer- 
land is possible and, in fact, very likely. First, the prob- 
able vector for the agent of HGE,  Ixodes ricinus, has a 
wide distribution in Switzerland and, depending on the 
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region, may transmit Borrelia burgdorferi and/or the 
central European tickborne encephalitis virus. Second, 
we recently reported a new subspecies of the Ehrlichia 
phagocytophila genogroup in dogs in Switzerland [11]; 
of the 16S rRNA gene this subspecies had a 100% ho- 
mology with that of the agent of HGE [12]. 
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